These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 31899769

  • 1. Development of a risk score for prediction of poor treatment outcomes among patients with multidrug-resistant tuberculosis.
    Alene KA, Viney K, Gray DJ, McBryde ES, Xu Z, Clements ACA.
    PLoS One; 2020; 15(1):e0227100. PubMed ID: 31899769
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
    Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, Gray DJ, Xu Z, Clements ACA.
    PLoS One; 2018; 13(5):e0197880. PubMed ID: 29791488
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC.
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D, Assefa T, Aman R, Tekalegn Y, Hailemariam Z.
    PLoS One; 2019 Mar; 14(10):e0224025. PubMed ID: 31665154
    [Abstract] [Full Text] [Related]

  • 7. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Kim CK, Koh WJ.
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [Abstract] [Full Text] [Related]

  • 8. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L, Meng Q, Chen S, Zhang M, Chen B, Wu B, Yan G, Wang X, Jia Z.
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [Abstract] [Full Text] [Related]

  • 9. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
    Kassa GM, Teferra AS, Wolde HF, Muluneh AG, Merid MW.
    BMC Infect Dis; 2019 Sep 18; 19(1):817. PubMed ID: 31533661
    [Abstract] [Full Text] [Related]

  • 10. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.
    Int J Tuberc Lung Dis; 2012 Oct 18; 16(10):1335-43. PubMed ID: 23107633
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S.
    BMC Infect Dis; 2017 Sep 29; 17(1):655. PubMed ID: 28962599
    [Abstract] [Full Text] [Related]

  • 14. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.
    Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, Prasad P, Prasad R, Fekade B, Tedla Y, Yusuf H, Tadesse M, Tefera D, Ashenafi A, Desta G, Aderaye G, Olson K, Thim S, Goldfeld AE.
    Thorax; 2015 Dec 29; 70(12):1181-8. PubMed ID: 26506854
    [Abstract] [Full Text] [Related]

  • 15. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H, van den Hof S, Cobelens F, Zhou Y, Zhao B, Wang S, Zhao Y.
    BMC Infect Dis; 2020 Jan 07; 20(1):19. PubMed ID: 31910878
    [Abstract] [Full Text] [Related]

  • 16. High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis.
    Yang Z, Zhou C, Ning Z, Lu W, Zhao Q, Hu Y, Diwan VK, Xu B.
    Glob Health Action; 2018 Jan 07; 11(1):1500763. PubMed ID: 30203719
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.
    Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC.
    Int J Tuberc Lung Dis; 2012 Jun 07; 16(6):805-11. PubMed ID: 22390880
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK.
    J Formos Med Assoc; 2016 Nov 07; 115(11):997-1003. PubMed ID: 26696497
    [Abstract] [Full Text] [Related]

  • 20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.